Scientists continue to make remarkable progress in the treatment of type 1 diabetes, in a move that could change the future of dealing with this chronic disease.
In a recent study, a team of scientists managed to treat the disease in mice using a new approach that does not require long-term suppression of the immune system, which had been one of the biggest obstacles to the success of insulin-producing cell transplants.
Type 1 diabetes occurs when the immune system attacks the insulin-producing cells in the pancreas, known as the islets of Langerhans. As a result, the body loses its ability to regulate blood sugar levels, forcing patients to rely on insulin injections for life, with the risk of health complications remaining.
Scientists have long tried to treat this defect by transplanting new cells capable of producing insulin, but the body often rejects these cells, which necessitates the use of powerful drugs to permanently suppress the immune system, thus limiting the spread of this treatment.
But the new study offered a different solution; scientists developed a "merged" immune system that combines characteristics of both the donor and the recipient. This merging helped the immune system accept the transplanted cells instead of attacking them.
To achieve this, the team used a combination of antibodies and low doses of radiation along with a drug commonly used to treat arthritis. This method allowed them to introduce stem cells from the donor into the recipient's bone marrow without having to completely destroy their immune system.
Over time, these new cells helped to "retrain" the immune system, so that it stopped attacking insulin-producing cells and even recognized them as a normal part of the body.
The results showed that the mice continued to produce insulin for a long time after treatment, without showing signs of rejection of the transplanted cells, which is a promising indication of the success of this approach.
However, scientists emphasize that there is still a long way to go before this technology can be applied to humans. Several challenges remain, including the difficulty of obtaining suitable cells and the need to maintain a delicate balance within the new immune system over extended periods.
If future studies succeed in overcoming these obstacles, this discovery could open the door to effective treatment, and perhaps even a cure, for type 1 diabetes, instead of merely managing it as is the case today.
